NICE prefers cheaper Humira in Crohn's disease
This article was originally published in Scrip
NICE has drafted guidance for the national health service in England and Wales that recommends both Abbott's Humira (adalimumab) and Schering-Plough's Remicade (infliximab, licensed from Johnson & Johnson) for the treatment of some patients with Crohn's disease.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.